{
  "asset": "CARVYKTI (Ciltacabtagene autoleucel)",
  "query_terms": [
    "CARVYKTI (Ciltacabtagene autoleucel)",
    "Ciltacabtagene autoleucel",
    "CARVYKTI"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT06623630",
      "title": "A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Washington University School of Medicine",
      "collaborators": [
        "American Cancer Society, Inc.",
        "Cures Within Reach"
      ],
      "interventions": [
        "Cyclophosphamide",
        "Ciltacabtagene Autoleucel",
        "Total body irradiation"
      ],
      "last_update": "2025-12-29",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06623630"
    },
    {
      "nct_id": "NCT05201781",
      "title": "Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Cilta-cel"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05201781"
    },
    {
      "nct_id": "NCT07149857",
      "title": "A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Cilta-cel",
        "Cyclophosphamide",
        "Induction therapy",
        "Fludarabine"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07149857"
    },
    {
      "nct_id": "NCT06577025",
      "title": "A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Cilta-cel",
        "Talquetamab",
        "Daratumumab",
        "Teclistamab",
        "Bortezomib",
        "Lenalidomide",
        "Dexamethasone",
        "Cyclophosphamide",
        "Fludarabine"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06577025"
    },
    {
      "nct_id": "NCT04923893",
      "title": "A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Bortezomib",
        "Dexamethasone",
        "Lenalidomide",
        "Cilta-cel",
        "Cyclophosphamide",
        "Fludarabine"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04923893"
    },
    {
      "nct_id": "NCT05346835",
      "title": "Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma",
      "overall_status": "AVAILABLE",
      "phase": null,
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Scientific Affairs, LLC",
      "collaborators": [],
      "interventions": [
        "Cilta-cel OOS Therapy"
      ],
      "last_update": "2025-08-27",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05346835"
    },
    {
      "nct_id": "NCT05767359",
      "title": "CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma",
        "Smoldering Multiple Myeloma"
      ],
      "lead_sponsor": "Dana-Farber Cancer Institute",
      "collaborators": [
        "Janssen Research & Development, LLC"
      ],
      "interventions": [
        "Ciltacabtagene Autoleucel",
        "Cyclophosphamide",
        "Fludarabine Phosphate"
      ],
      "last_update": "2025-09-11",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05767359"
    },
    {
      "nct_id": "NCT05347485",
      "title": "A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Janssen Scientific Affairs, LLC",
      "collaborators": [],
      "interventions": [
        "Cilta-cel",
        "Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)"
      ],
      "last_update": "2025-04-25",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05347485"
    },
    {
      "nct_id": "NCT07093554",
      "title": "Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma",
      "overall_status": "RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Relapse Multiple Myeloma",
        "Refractory Multiple Myeloma"
      ],
      "lead_sponsor": "Medical College of Wisconsin",
      "collaborators": [],
      "interventions": [
        "Talquetamab",
        "Ciltacabtagene Autoleucel"
      ],
      "last_update": "2026-01-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07093554"
    },
    {
      "nct_id": "NCT03758417",
      "title": "A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Nanjing Legend Biotech Co.",
      "collaborators": [
        "Janssen Research & Development, LLC"
      ],
      "interventions": [
        "LCAR-B38M CAR-T Cell"
      ],
      "last_update": "2025-12-17",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03758417"
    }
  ]
}